Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:CRGX NASDAQ:KRON NASDAQ:NLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.43$1.97$1.43▼$4.26$244M1.62140,833 shs230,276 shsCRGXCARGO Therapeutics$4.52$4.38$3.00▼$25.45$208.42M0.282.93 million shs1.12 million shsKRONKronos Bio$0.88+1.5%$0.81$0.65▼$1.46$53.72M1.64370,931 shs54,089 shsNLTXNeoleukin Therapeutics$22.72-0.4%$19.61$2.03▼$14.36$213.52M1.1150,104 shs75,610 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+17.39%+17.39%+48.17%-31.16%CRGXCARGO Therapeutics0.00%-1.09%+9.18%+0.22%-73.93%KRONKronos Bio0.00%0.00%0.00%+3.41%-33.33%NLTXNeoleukin Therapeutics-1.21%+0.93%+32.62%+48.02%-46.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.0651 of 5 stars3.51.00.00.03.30.80.6CRGXCARGO Therapeutics1.9812 of 5 stars2.90.00.00.01.91.71.3KRONKronos BioN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00393.83% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40240.71% UpsideKRONKronos Bio 2.33Hold$1.6384.66% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KRON, CRGX, NLTX, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M7.87N/AN/A$1.29 per share1.88CRGXCARGO TherapeuticsN/AN/AN/AN/A$7.83 per shareN/AKRONKronos Bio$9.85M5.45N/AN/A$1.45 per share0.61NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)KRONKronos Bio-$86.08M-$1.07N/AN/AN/A-701.53%-64.22%-47.17%8/6/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ALatest KRON, CRGX, NLTX, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRGXCARGO Therapeutics-$0.42N/AN/AN/AN/AN/A8/5/2025Q2 2025ACIUAC Immune-$0.18N/AN/AN/A$1.98 millionN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.531.53CRGXCARGO TherapeuticsN/A6.306.30KRONKronos BioN/A12.9312.93NLTXNeoleukin TherapeuticsN/A15.3315.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%CRGXCARGO Therapeutics93.16%KRONKronos Bio64.09%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%CRGXCARGO Therapeutics2.92%KRONKronos Bio24.40%NLTXNeoleukin Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableCRGXCARGO Therapeutics11646.11 million44.76 millionN/AKRONKronos Bio10061.05 million46.16 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataKRON, CRGX, NLTX, and ACIU HeadlinesRecent News About These CompaniesNeoleukin Therapeutics (NASDAQ:NLTX) Stock Price Down 1.2% - Should You Sell?July 23 at 3:07 AM | marketbeat.comNeoleukin Therapeutics (NASDAQ:NLTX) Shares Down 7.5% - Should You Sell?July 1, 2025 | marketbeat.com(NGNE) Proactive StrategiesOctober 18, 2024 | news.stocktradersdaily.comNNeurogene concludes merger deal with Neoleukin TherapeuticsDecember 20, 2023 | pharmaceutical-technology.comPIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 14, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%September 26, 2023 | dhakatribune.comDNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must KnowAugust 21, 2023 | knoxdaily.comKNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comAnalysts review Neoleukin Therapeutics Inc.’s ratingJuly 26, 2023 | knoxdaily.comKALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFJuly 24, 2023 | kentuckytoday.comKBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRON, CRGX, NLTX, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$2.43 0.00 (0.00%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.62%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.CARGO Therapeutics NASDAQ:CRGX$4.52 0.00 (0.00%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.52 0.00 (0.00%) As of 07/25/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Kronos Bio NASDAQ:KRONKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Neoleukin Therapeutics NASDAQ:NLTX$22.72 -0.09 (-0.39%) As of 07/25/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
